First Human Clinical Trial Begins for Leishmaniasis Vaccine as Cases Emerge in U.S.

Researchers are launching a phase 1 clinical trial to evaluate the safety of a new vaccine designed to prevent leishmaniasis, a disfiguring skin disease. This study marks the first time a vaccine candidate for the condition has reached human testing as the disease expands its geographic reach into the United States.

The trial will begin in the coming months to assess how the human body reacts to the vaccine. Leishmaniasis, which is traditionally prevalent in tropical regions, causes significant skin lesions and other health complications. Health officials have observed the disease appearing more frequently in the United States, prompting the development of this preventative measure. Scientists intend to use the data from this initial phase to determine if the vaccine warrants further study in larger clinical trials.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 6, 2026

Author

GOAI